Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus R-GDP versus R-GDP in relapsed or refractory diffuse large B-cell lymphoma
CTR20211969Phase 3Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Karyopharm Therapeutics Inc.. Started Dec 2021; status: terminated.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20211969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211969.